Inside the FDA's Commissioner's National Priority Voucher Program: Promise, Pressure, and Operational Reality

When the FDA launched the Commissioner's National Priority Voucher (CNPV) program in mid-2025, it represented one of the most aggressive regulatory timeline compressions in modern drug development.¹

The premise was straightforward: sponsors developing therapies that address urgent domestic health needs could receive a voucher enabling the FDA to complete its review in as little as one to two months, compared to the standard 10-12 month window.

Following the agency’s green light on Bizengri for the treatment of NRG1 fusion-positive cholangiocarcinoma earlier this month, seven approvals have been made under the CNPV program, and 18 vouchers have been awarded.²

Additionally, at least one high-profile controversy has emerged, and the operational implications for sponsors and CROs are coming into sharper focus.

How does the CNPV program work?

The CNPV program was designed around a multidisciplinary "tumor board-style" review model—an approach former FDA Commissioner Marty Makary, MD, MPH drew explicitly from his background as a surgical oncologist.

Rather than the fragmented sequential review that characterizes a standard New Drug Application (NDA), a designated team of FDA physicians and scientists conducts a pre-review of submitted materials followed by a single collaborative meeting to evaluate data and reach a decision.

"Using a common-sense approach, the national priority review program will allow companies to submit the lion's share of the drug application before a clinical trial is complete so that we can reduce inefficiencies," Makary said at launch. "The ultimate goal is to bring more cures and meaningful treatments to the American public."

To qualify, sponsors must submit the chemistry, manufacturing, and controls section of their application along with draft labeling at least 60 days before filing the complete application, meaning manufacturing must reach commercial readiness earlier than a standard NDA requires.

Sponsors must also maintain consistent, responsive communication with FDA reviewers throughout the process. The FDA retains the right to extend review if data are incomplete, ambiguous, or the application presents unusual complexity.

Sara Brenner, principal deputy commissioner at the FDA, emphasized at the time that the model was not designed to cut corners.

"This approach capitalizes on frequent communication with sponsors, which can be a powerful tool in reducing wasted time. We are confident this more efficient process can be achieved without cutting any corners on safety or scientific evaluation," she said.

What vouchers were initially awarded?

The first round of nine vouchers covered a range of disease areas and national priorities, including therapies for infertility, type 1 diabetes, nicotine vaping addiction, deafness, blindness, pancreatic cancer, porphyria, and two awards tied to domestic manufacturing of ketamine and Augmentin XR.

A second round added six more, covering HER2-positive lung cancer, drug-resistant tuberculosis in children, rectal cancer, sickle cell disease, and two obesity treatments—orforglipron and Wegovy.³

What it takes to succeed under CNPV timelines

Applied Clinical Trials spoke exclusively with John Kirk, principal regulatory strategist at Veristat, about what the program demands from sponsors and CROs at the operational level. The picture he paints is one of total cross-functional integration from the earliest stages of development.

The compressed timeline creates immediate pressure on data readiness. Clinical trials needed for the marketing application must be completed on time and meet a high-quality bar to support review and pre-approval inspections.

At the same time, the short review window means any FDA information requests must be addressed on very short notice—a requirement that can derail the entire timeline if teams are not prepared.

"Sponsors who successfully navigate these compressed timelines integrate their biostatistics, regulatory, and medical writing teams from the outset, creating a unified approach where data flows seamlessly from analysis through narrative to submission, rather than treating these as sequential handoffs," Kirk said.

The model of enhanced communication under the CNPV program is comparable in some ways to what sponsors experience under Breakthrough Therapy designation, Kirk noted. FDA senior staff become more proactive and frequent in their information requests, and in return are more responsive to sponsor needs. However, that dynamic only works if both sides are organized enough to sustain it.

"At Veristat, we have faced 24-hour turnarounds to FDA queries—and success always depends on our regulatory, biostatistics, and medical writing teams seamlessly functioning as a single unit," Kirk said. "The ability to provide comprehensive responses quickly often comes down to having established workflows where team members already understand each other's processes and can mobilize fast. Rapid response teams by functional area are also necessary, with clear escalation paths and pre-aligned decision-making authority to avoid bottlenecks."

For sponsors aiming to qualify for a CNPV in the first place, early-phase decisions carry outsized weight. The accelerated approval (AA) pathway that often accompanies CNPV eligibility depends on a biomarker qualified as a surrogate endpoint reasonably likely to predict clinical benefit.

The FDA must agree on that endpoint before the program can move forward. Not every product is associated with a plausible biomarker, and even those that are may not be able to demonstrate the surrogate's predictive value for clinical benefit.

Kirk emphasized that those assessments need to happen early.

"The complexity of AA requirements means that strategic decisions made in early development can significantly impact the viability of the accelerated pathway years later," Kirk said. "We've found that bringing regulatory, clinical, and biostatistics expertise together during initial protocol design helps sponsors avoid costly pivots later in development."

Veristat has attended Type C meetings alongside sponsors to provide real-time strategic input during FDA guidance discussions. Kirk described these as pivotal moments where agency feedback can reshape entire development programs.

The preparation that goes into those interactions matters as much as the meetings themselves, with teams working through anticipated FDA questions, comprehensive briefing packages, and contingency strategies in advance.

Controversy and a high-profile withdrawal request

The CNPV program has not been without turbulence. Since its launch, questions have been raised about whether the voucher mechanism could be used to reward political allies in the biopharma industry—a criticism that has followed the program through much of its first year.⁴

The most concrete sign of strain came when Sanofi, according to Fierce Pharma, asked that its application for an expanded use of its Type 1 diabetes drug Tzield be removed from the CNPV track.

According to reporting from Stat, cited by Fierce Pharma, the request followed a decision by CDER acting director Tracy Beth Høeg to overturn a staff recommendation to approve the treatment. An April 21 decision date passed without a complete response letter being issued.

Tzield was originally approved in 2022 to delay the onset of stage 3 type 1 diabetes in adults and children eight and older. The CNPV application concerned a potential expansion to slow disease progression in that same age group already at stage 3, the point at which clinical diagnosis typically occurs.

The FDA had delayed its review of the application in January following reports of two seizures and one death from blood clotting, though staff subsequently determined the risks could be managed through labeling.

Sanofi declined to comment directly on the reported withdrawal request, noting only that it remained confident in Tzield's efficacy and safety profile and committed to working with the FDA through the review process.

Notably, Sanofi was not among the initial group of sponsors who applied for a CNPV. The FDA nominated the big pharma to receive one because its application addressed an unmet need.

The operational takeaway

The CNPV program is still young, and its long-term track record has yet to be established. The early evidence suggests the sponsors best positioned to benefit are those who approach the program not as a faster version of standard development, but as a fundamentally different operating model that demands tighter integration, earlier readiness, and a level of cross-functional coordination that most organizations will need to deliberately build.

"Early planning and close partnership between the sponsor and CRO are critical to success," Kirk said. "Having experienced team members who understand both the scientific nuances and regulatory expectations—and who can think quickly during these discussions—helps sponsors maximize the value of these limited FDA interactions."

References

1. FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies. Applied Clinical Trials. June 18, 2025. Accessed May 21, 2026. https://www.appliedclinicaltrialsonline.com/view/fda-national-priority-voucher-program

2. FDA Grants Seventh Approval under the National Priority Voucher Pilot Program. News release. FDA. May 8, 2026. Accessed May 21, 2026. https://www.fda.gov/news-events/press-announcements/fda-grants-seventh-approval-under-national-priority-voucher-pilot-program

3. How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies. Applied Clinical Trials. December 1, 2025. Accessed May 21, 2026. https://www.appliedclinicaltrialsonline.com/view/how-fda-cnpv-program-reshaping-trial-operations-accelerated-review-strategies

4. Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report. Fierce Pharma. May 6, 2026. Accessed May 21, 2026. https://www.fiercepharma.com/pharma/sanofi-requests-exit-controversial-cnpv-fast-track-program-stat